FULC
Fulcrum Therapeutics Inc

2,311
Mkt Cap
$642.55M
Volume
489,219.00
52W High
$15.74
52W Low
$2.32
PE Ratio
-8.26
FULC Fundamentals
Price
$9.74
Prev Close
$9.55
Open
$9.71
50D MA
$11.02
Beta
1.57
Avg. Volume
777,958.15
EPS (Annual)
-$0.1569
P/B
2.66
Rev/Employee
$1.78M
Loading...
Loading...
News
all
press releases
Campbell & CO Investment Adviser LLC Takes Position in Fulcrum Therapeutics, Inc. $FULC
Campbell & CO Investment Adviser LLC acquired a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the third quarter, according to its most recent 13F filing with...
MarketBeat·19d ago
News Placeholder
More News
News Placeholder
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twelve research firms that are covering the firm, Marketbeat Ratings reports. Three...
MarketBeat·20d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Cut to Sell at Wall Street Zen
Wall Street Zen lowered shares of Fulcrum Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·22d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Up - Should You Buy?
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Up - Still a Buy...
MarketBeat·26d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Coverage Initiated by Analysts at JPMorgan Chase & Co.
JPMorgan Chase & Co. began coverage on shares of Fulcrum Therapeutics in a report on Monday. They set an "overweight" rating and a $20.00 price target for the company...
MarketBeat·26d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Director Robert Gould Sells 15,000 Shares
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) Director Robert Gould sold 15,000 shares of Fulcrum Therapeutics stock in a transaction dated Friday, January 2nd. The shares were sold at...
MarketBeat·1mo ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 5.4% - Should You Sell?
Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 5.4% - Here's Why...
MarketBeat·1mo ago
News Placeholder
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Significant Decrease in Short Interest
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw a large decline in short interest in December. As of December 15th, there was short interest totaling 2,994,328 shares, a decline of...
MarketBeat·1mo ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Trading Down 4.3% - Time to Sell?
Fulcrum Therapeutics (NASDAQ:FULC) Trading Down 4.3% - Here's Why...
MarketBeat·1mo ago
News Placeholder
Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 58.5% in Fulcrum Therapeutics (FULC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·1mo ago
<
1
2
...
>

Latest FULC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.